



Supplementary Figure S1: antibody reactivity to the spikes of different SARS-CoV-2 variants

(A-F) Antibodies specific to the spikes of the different SARS-CoV-2 variants of concern were measured in patient and control sera by a multiplexed Luminex assay. The spikes tested included that of the original Wuhan strain (A) and those of the Alpha, Beta, Delta, Gamma, and Omicron BA.1 variants (B-F), respectively. The mean fluorescent intensity (MFI) measured for human IgG is reported. HD: healthy donors; LC-: seronegative long COVID patients; LC+: seropositive long COVID patients; RE: recovered patients. Horizontal bars represent medians. Differences between groups were evaluated with the Kruskal-Wallis statistical test with Dunn's correction for multiple comparisons. **** $P<0.0001$.



Supplementary Figure S2: antibody reactivity to other viruses

(A-F) Antibodies specific to viruses unrelated to SARS-CoV-2 were measured in patient and control sera by a multiplexed Luminex assay. The antigens tested were derived from influenza A virus (A), adenovirus 5 (B), adenovirus 40 (C), measles virus (D), rubella virus (E), and mumps virus (F). The mean fluorescent intensity (MFI) measured for human IgG is reported. HD: healthy donors; LC-: seronegative long COVID patients; LC+: seropositive long COVID patients; RE: recovered patients. Horizontal bars represent medians. Differences between groups were evaluated with the Kruskal-Wallis statistical test with Dunn's correction for multiple comparisons. * P<0.05; ** P<0.01.



Supplementary Figure S3: correlation matrix of clinical and immunological parameters evaluated in the PERSICOT study
 Spearman correlation coefficients are color-coded according to the scale bar (right)

Spike

<i>S</i> 166	CTFEYVSQPFLMDLEGHQGN
<i>S</i> 235	ITRFQTLLALHRSYLTPGDS
<i>S</i> 751	NLLLQYGSFCTQLNALTGI

Matrix

<i>M</i> 86	CLVGLMWLSYFIASFRLFAR
<i>M</i> 141	GAVILRGHLRIAGHHHLGRCD
<i>M</i> 176	LSYYKLGASQRVAGDSGFAA

Nucleocapsid

<i>N</i> 104	LSPRWYFYYLGTGPEAGLPY
<i>N</i> 221	LLLLDRLNQLESKMSGKGQQ
<i>N</i> 328	GTWLTYTGAIKLDDKDPNKF

Supplementary Table 1: List of 20-mer peptides used to generate primary CD4+ T cell lines

Each peptide is named after the SARS-CoV-2 viral protein it originates from (S, M, or N) and the number of the first amino acid in the relevant protein.